Similar articles

• [Immunosuppressive therapy for nephrotic syndrome and strategy for adverse side effects from that therapy].

  Takeda Y, Tomino Y. Takeda Y, et al. Nihon Rinsho. 2004 Oct;62(10):1875-9. Nihon Rinsho. 2004. PMID: 15500133 Review. Japanese.
• [Immunosuppressive therapy update 2010 for ANCA-associated glomerulonephritis and intractable nephrotic syndrome].

  Yoshida M. Yoshida M. Nihon Jinzo Gakkai Shi. 2010;52(1):1-9. Nihon Jinzo Gakkai Shi. 2010. PMID: 20166533 Review. Japanese. No abstract available.
• [Treatment guidelines for the idiopathic nephrotic syndrome in children].

  Yoshikawa N, Honda M, Sekine K, Nakanishi K, Iijima I, Ootomo Y, Ikeda M, Wada N, Nakamura H, Sako M; Japanese Society of Nephrology Committee for Development of Guidelines for Drug Therapy for Nephrotic Syndrome in Children. Yoshikawa N, et al. Nihon Jinzo Gakkai Shi. 2005;47(7):790-803. Nihon Jinzo Gakkai Shi. 2005. PMID: 16296409 Japanese. No abstract available.
• Role of mycophenolate mofetil in remission maintenance after a successful response to rituximab.

  Sharma AP, Filler G. Sharma AP, et al. Pediatr Nephrol. 2009 Feb;24(2):423-4. doi: 10.1007/s00467-008-1030-8. Epub 2008 Oct 14. Pediatr Nephrol. 2009. PMID: 18853197 No abstract available.
• Non-steroidal and non-cytotoxic therapies for nephrotic syndrome.

  Coppo R. Coppo R. Nephrol Dial Transplant. 2008 Jun;23(6):1793-6. doi: 10.1093/ndt/gfn211. Epub 2008 Apr 25. Nephrol Dial Transplant. 2008. PMID: 18441003 No abstract available.